A Multicenter Randomized, Double-blind, Placebo-controlled Phase 2 Study to Evaluate Efficacy, Safety, Tolerability, Pharmacokinetics and Target Engagement of GSK3858279 in Adult Participants With Chronic Diabetic Peripheral Neuropathic Pain (DPNP) /NEPTUNE-17

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 22 Nov 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs GSK-3858279 (Primary)
Indications Diabetic neuropathies; Neuropathic pain
Focus Therapeutic Use
Acronyms NEPTUNE-17
Sponsors GlaxoSmithKline; GSK

Most Recent Events

18 Nov 2024 Planned End Date changed from 6 Oct 2025 to 23 Jan 2025.
18 Nov 2024 Status changed from recruiting to active, no longer recruiting.
20 Sep 2024 Planned End Date changed from 24 Jun 2025 to 6 Oct 2025.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight